
I focus on capital allocation in AI-enabled clinical infrastructure and advanced therapeutics, with an emphasis on regulatory inflection points and capital efficiency. Over two decades in global pharmaceutical and biotechnology environments, I have evaluated clinical-stage assets, conducted transaction due diligence, and operated within governance structures spanning regulatory approval and commercialization. This experience informs how I assess risk, timing, and value creation in healthcare investments. My investment lens centers on three questions: • Where does regulatory reality diverge from founder assumptions? • What is the true capital required to reach the next value inflection? • Which companies can scale within clinical systems without structural friction? I focus on companies building durable infrastructure for clinical decision-making, AI-enabled workflows, and scalable drug-development platforms. My background includes an MD and an MPH from Harvard T.H. Chan School of Public Health, with formal training in clinical epidemiology, biostatistics, and decision analysis, as well as advanced coursework in artificial intelligence and machine learning. 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗔𝗹𝗹𝗼𝗰𝗮𝘁𝗶𝗼𝗻 & 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗘𝘅𝗽𝗼𝘀𝘂𝗿𝗲 • Member, Harvard Business School Alumni Angels • Advisor, SPARK program at Stanford • Experience in transaction diligence across pharmaceutical and biotech assets • Chairperson, Independent Data Safety Monitoring Board at Rapport Therapeutics
Attending Physician
Medical School
1984
Residency